1 307

Cited 0 times in

Clinical significance of insulin receptor substrate-I down-regulation in non-small cell lung cancer

 Chang Hoon Han  ;  Jae Yong Cho  ;  Jong Tae Moon  ;  Hyung Jung Kim  ;  Se Kyu Kim  ;  Dong Hwan Shin  ;  Joon Chang  ;  Chul Min Ahn  ;  Sung Kyu Kim  ;  Yoon Soo Chang 
 ONCOLOGY REPORTS, Vol.16(6) : 1205-1210, 2006 
Journal Title
Issue Date
Biomarkers, Tumor/analysis ; Carcinoma, Non-Small-Cell Lung/metabolism* ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/pathology* ; Carcinoma, Squamous Cell/metabolism ; Carcinoma, Squamous Cell/mortality ; Carcinoma, Squamous Cell/pathology ; Down-Regulation ; Female ; Humans ; Immunohistochemistry ; Insulin Receptor Substrate Proteins ; Lung Neoplasms/metabolism* ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology* ; Male ; Middle Aged ; Neoplasm Staging ; Phosphoproteins/biosynthesis* ; Prognosis ; Smoking ; Survival Analysis
Insulin receptor substrate-1 (IRS-1) is an adaptor protein for insulin-like growth factor (IGF) signaling and it is presumed associated with cancer development, progression or clinical outcome of patients harboring solid tumors. Therefore, we investigated by immunohistochemistry, the expression of IRS-1 in the tumor tissues from 94 patients who were diagnosed as stage I non-small cell lung cancer (NSCLC) and had undergone a curative lung resection. The relationships between its intratumoral expression and various clinical parameters were explored. IRS-1 is consistently expressed in the cytoplasm of intrapulmonary bronchial and bronchiolar epithelial cells comprising normal appearing adjacent lung tissues. Forty-one (43.6%) of 94 specimens showed loss of IRS-1 expression. In a subset analysis, IRS-1 was more frequently lost in stage IB than in IA tumors (50.0 vs. 22.7%, p=0.024, χ2 test), which was reflected by the facts that tumors which showed down-regulation of IRS-1 had larger area than those with IRS-1 expression (18.1 vs. 12.1 cm2, p=0.044, t-test). Down-regulation of IRS-1 is more frequently observed in squamous cell carcinoma than other cell type lung cancer (p=0.002, χ2 test) and its expression was not affected by histological grade of differentiation. Comparing pack-years (P.Y.) between groups of smokers whose tumor expressed IRS-1 and those that did not, smokers whose tumor showed loss of IRS-1 expression had higher P.Y. than those whose tumor did express IRS-1 (39.2±23.67 vs. 25.6±26.61 P.Y., p=0.034, t-test). Intratumoral expression of IRS-1 did not influence disease-free survival, disease-specific survival or overall survival of stage I NSCLC patients, whose median follow-up duration is 7.5 years (95% CI; 7.21-7.86 years). These results suggest that loss of IRS-1 might rather be an early event in NSCLC development than a prognostic factor and that it is more strongly related with squamous cell carcinoma and with smoking.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Sung Kyu(김성규)
Kim, Se Kyu(김세규)
Kim, Hyung Jung(김형중) ORCID logo https://orcid.org/0000-0003-2498-0683
Shin, Dong Hwan(신동환)
Ahn, Chul Min(안철민)
Chang, Yoon Soo(장윤수) ORCID logo https://orcid.org/0000-0003-3340-4223
Chang, Joon(장준) ORCID logo https://orcid.org/0000-0003-4542-6841
Cho, Jae Yong(조재용) ORCID logo https://orcid.org/0000-0002-0926-1819
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.